Message #3 From:
Stock News Bot Date: July 26, 2005 04:00:00 AM
ADVR News ADVR Awarded U.S. Patent for AVR118
YONKERS, N.Y.--(BUSINESS WIRE)--July 26, 2005--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) announced today that the U.S. Patent and Trademark Office has issued the Company U.S. Patent No. 6,921,542 entitled "Preparation of a Therapeutic Composition" for AVR118. The patent covers pharmaceutical compositions of AVR118 and a pharmaceutically acceptable carrier.
"Broad patent protection is essential for the Company," said Dr. Elma S. Hawkins, President and CEO of Advanced Viral Research Corp. "We are pleased to expand our AVR118 patent portfolio with another issued U.S. patent."
Currently, ADVR is engaged in a Phase II, multi-center, randomized, double-blind United States study designed to evaluate the effect of a 4.0 ml dose of AVR118 administered to patients with systemic symptoms related to advanced cancers who are not candidates for, or who do not wish to receive, chemotherapy.
ADVR's AVR118 represents a biopolymer that possesses novel immunomodulatory activity. This peptide-nucleic acid complex, which to date has demonstrated a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus, and to dampen aberrant autoimmune-type inflammatory responses, such as those which occur in patients with rheumatoid arthritis.
The Phase I/II clinical trial of AVR118 in AIDS patients, which was conducted in Israel, concluded that AVR118 continues to demonstrate evidence of unique patient benefits, a favorable safety profile, and no apparent drug-related adverse events. Unique patient benefits included weight gain, mood improvement, decrease in fatigue, and increase in ability to perform everyday tasks.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
